Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2005

View Archived Issues

Preliminary phase IIb results on the effects of oral insulin spray in type 1 diabetes

MedImmune amends agreement with GSK for HPV vaccine

NM-100060 enters phase I study for onychomycosis

IND accepted for Norwood Abbey's autologous bone marrow transplant study

VP-025 for neuroinflammatory disorders enters phase I study

Pfizer submits lasofoxifene sNDA for treatment of vaginal atrophy

ViroLogic signs service agreement to support GSK HIV drug development

Premarket approval for BioGenex' InSite Her-2/neu Kit

Basilea enters global agreement with Cilag for ceftobiprole

HIV protease inhibitor PL-100 successfully completes viral crossresistance study

Enzon to discontinue pegamotecan development

FDA accepts BiDil NDA resubmission

Proxinium awarded orphan drug status for recurrent head and neck cancer

First phase III trial of an HIV vaccine shows no success in preventing infection

SR-147778: further evidence that CB1 antagonism may be effective for the treatment of alcoholism

T-type Ca2+ channel, therapeutic target for epilepsy and neuropathic pain, is blocked by KYS-05044

Telmisartan improves cerebral blood flow autoregulation in SHR

Neuroprotective effects of the PAF antagonist, LAU-0901, shown in a mouse transient ischemia model

Janssen publishes preclinical results for R-126638

Preclinical data on dual thromboxane synthase inhibitor and thromboxane receptor antagonist

AstraZeneca presents new P2X7 receptor antagonists

Phase II data on the effects of secretin in schizophrenia

Aurora kinase inhibitors developed at AstraZeneca

Novel antiviral agents in early development at BioCryst

BMS claims calcium-sensing receptor antagonists with utility in bone disorders

IKK inhibitors covered by Bristol-Myers Squibb patent

Patent discloses new antimitotic agents for cancer

Bosentan reported to improve survival of patients with primary pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...